Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Study Completion Date

July 31, 2009

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG

AZD4877

intravenous infusion administered on days 1, 2 and 3

Trial Locations (4)

Research Site, Chicago

Research Site, Houston

Research Site, San Antonio

Research Site, Toronto